CCO

Calfee, Halter & Griswold Partner Patrick Hayes Co-Authors The NSCP Firm and CCO Liability Framework Guide

Retrieved on: 
Wednesday, January 19, 2022 - 6:43pm

Cincinnati, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Patrick D. Hayes , Partner and Investment Management practice leader at the law firm of Calfee, Halter & Griswold LLP and member of the National Society of Compliance Professionals (NSCP) Board of Directors, recently co-authored The NSCP Firm and CCO Liability Framework, a guide providing a practical approach to the topic of chief compliance officer (CCO) liability.

Key Points: 
  • Cincinnati, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Patrick D. Hayes , Partner and Investment Management practice leader at the law firm of Calfee, Halter & Griswold LLP and member of the National Society of Compliance Professionals (NSCP) Board of Directors, recently co-authored The NSCP Firm and CCO Liability Framework, a guide providing a practical approach to the topic of chief compliance officer (CCO) liability.
  • The results of the surveys were incredibly instructive and provided the baseline for the Regulatory Advisory Committee to develop The NSCP Firm and CCO Liability Framework, said Hayes.
  • The NSCP Firm and CCO Liability Framework ("NSCP Framework [1] ") provides a practical approach to the topic and complements an earlier publication by the New York City Bar Association titled New York City Bar Association White Paper on CCO Liability.
  • The NSCP Framework states, To more effectively address the issue of CCO liability, the NSCP believes it is necessary to focus on the larger context of the compliance function within firms and to do so earlier in regulatory reviews, whether during examinations or enforcement investigations.A copy of The NSCP Firm and CCO Liability Framework guide provides additional details.

Act-On Unveils 2022 Marketing Predictions

Retrieved on: 
Wednesday, January 19, 2022 - 2:00pm

Portland, Ore., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Act-On Software , the leading growth marketing automation platform, today unveiled its predictions for the marketing industry in 2022.

Key Points: 
  • Portland, Ore., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Act-On Software , the leading growth marketing automation platform, today unveiled its predictions for the marketing industry in 2022.
  • In the new year, centralization of marketing tools will increase as marketing pros require seamless integrations between software that are conducive to efficient, organized, and agile workflows.
  • Centralization of marketing tools will be a key component of successful marketing teams in 2022, said Gregg Ames, CCO of Act-On Software.
  • Centralization of technology keeps marketing teams more organized, efficient, and productive, and as a byproduct, is an effective way to both attract and retain marketing talent.

BioXcel Therapeutics Appoints Matt Wiley Chief Commercial Officer

Retrieved on: 
Wednesday, January 19, 2022 - 12:00pm

NEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Matt Wiley as Senior Vice President and Chief Commercial Officer (CCO).

Key Points: 
  • NEW HAVEN, Conn., Jan. 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Matt Wiley as Senior Vice President and Chief Commercial Officer (CCO).
  • We are pleased to welcome Matt to our management team, as we prepare for our first potential approval and commercial launch of BXCL501 for the acute treatment of agitation associated with schizophrenia and bipolar disorders, said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics.
  • He joins BioXcel Therapeutics from VYNE Therapeutics, where he served as CCO overseeing all commercial objectives related to the launch of the companys first two approved dermatology products, AMZEEQ and ZILXI.
  • BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

Retrieved on: 
Tuesday, January 18, 2022 - 12:00pm

Together, Sema4 and GeneDx will be one of the largest and most advanced providers of genomic clinical testing in the U.S., with a projected $350 million in pro forma 2022 revenue.

Key Points: 
  • Together, Sema4 and GeneDx will be one of the largest and most advanced providers of genomic clinical testing in the U.S., with a projected $350 million in pro forma 2022 revenue.
  • We are excited to join forces with Sema4, a market leader in using genomic and clinical data to deliver precision medicine, said Ms. Stueland.
  • Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories.
  • Sema4 believes that patients should be treated as partners, and that data should be shared for the benefit of all.

VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer

Retrieved on: 
Tuesday, January 18, 2022 - 1:00pm

His appointment further advances VBLs strategic plan to become a commercial organization and establish operations in the United States.

Key Points: 
  • His appointment further advances VBLs strategic plan to become a commercial organization and establish operations in the United States.
  • "We are delighted to have Matt join our leadership team, said Dror Harats, M.D., Chief Executive Officer of VBL.
  • Matthew Trudeau commented, I am very pleased to join VBL at this important time.
  • Matthew Trudeau brings over 25 years of U.S. and international experience commercializing complex biological products.

Havas Chicago Chief Creative Officer Myra Nussbaum Adds President to Title

Retrieved on: 
Wednesday, January 19, 2022 - 5:24pm

Less than a year after becoming chief creative officer of Havas Chicago, Myra Nussbaum has been promoted to the dual role of president and chief creative officer of the creative agency.

Key Points: 
  • Less than a year after becoming chief creative officer of Havas Chicago, Myra Nussbaum has been promoted to the dual role of president and chief creative officer of the creative agency.
  • Nussbaum, the first female CCO within Havas North American creative network, now adds agency leadership responsibilities to her current creative remit, which has been focused on creative development and advancement for Havas Chicagos entire portfolio of clients and teams since taking the helm in May 2021.
  • Now, Nussbaum will be responsible for the agencys strategic oversight and guidance to continue to positively position the Havas Chicago Village in the marketing marketplace.
  • View the full release here: https://www.businesswire.com/news/home/20220119005873/en/
    A funny thing happened as we were searching for our next amazing leader for Havas Chicago, said Stephanie Nerlich, CEO, Havas North America.

Tower Arch Capital Announces New Partner, CCO, and Banner 2021

Retrieved on: 
Wednesday, January 19, 2022 - 4:39pm

Previously, he held positions with HIG Capital in San Francisco, Charlesbank Capital Partners in Boston, and with The Parthenon Group in Boston.

Key Points: 
  • Previously, he held positions with HIG Capital in San Francisco, Charlesbank Capital Partners in Boston, and with The Parthenon Group in Boston.
  • Additionally, he has been involved in Tower Arch investments in Corbett Technology Solutions, Inc., OSM Worldwide, SnugZ USA, and Softvision.
  • Headquartered in Salt Lake City, Utah, Tower Arch Capital is a lower-middle market private equity firm with over $750 million under management.
  • Tower Arch brings operational, consulting, and financial expertise to small and mid-sized companies to help them scale and improve their operations.

FANAPLY EXPANDS LEADERSHIP TEAM WITH KEY HIRES

Retrieved on: 
Wednesday, January 19, 2022 - 3:00pm

Beyond her leadership at the organization, Maged will bring her extensive track record of innovation and building businesses in sports, entertainment and technology to continue to scale Fanaply and develop transformational platforms and partnerships.

Key Points: 
  • Beyond her leadership at the organization, Maged will bring her extensive track record of innovation and building businesses in sports, entertainment and technology to continue to scale Fanaply and develop transformational platforms and partnerships.
  • "Fanaply has been a pioneer in the NFT space with its best-in-class and differentiated product offering over the last three years.
  • I'm thrilled to join the team as we work to tell the Fanaply story and continue building on the foundation of its commercial efforts."
  • In addition to Maged, Fanaply is bringing on two key hires to lead its Business Development team.

Mammogen Inc. CEO Elizabeth Cormier-May Wins Illustrious Award with Business Worldwide Magazine

Retrieved on: 
Wednesday, January 19, 2022 - 9:00am

LONDON, Jan. 19, 2022 /PRNewswire/ -- Liz Cormier-May of Mammogen was named Biotechnology CEO of the Year – USA in the 2021 Global Corporate Excellence Awards.

Key Points: 
  • Theawards, run by Business Worldwide Magazine, seek to identify and honor the most respected companiesand C level executives in the world.
  • The aim is to reward outstanding performance,innovation,and ethics across international business and finance communities, covering a vast range of sectors.
  • Liz Cormier-May won the award for her visionary approach, which is changing the face of healthcare for women all over the world.
  • Mammogen uses a combination of data, technology, science and personal experience to challenge the status quo.

Mammogen Inc. CEO Elizabeth Cormier-May Wins Illustrious Award with Business Worldwide Magazine

Retrieved on: 
Wednesday, January 19, 2022 - 9:00am

Theawards, run by Business Worldwide Magazine, seek to identify and honor the most respected companiesand C level executives in the world.

Key Points: 
  • Theawards, run by Business Worldwide Magazine, seek to identify and honor the most respected companiesand C level executives in the world.
  • The aim is to reward outstanding performance,innovation,and ethics across international business and finance communities, covering a vast range of sectors.
  • Liz Cormier-May won the award for her visionary approach, which is changing the face of healthcare for women all over the world.
  • Mammogen uses a combination of data, technology, science and personal experience to challenge the status quo.